Literature DB >> 8996345

Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group.

R A Janknegt1, H M Zweers, K P Delaere, A G Kloet, S G Khoe, H J Arendsen.   

Abstract

PURPOSE: We evaluated the efficacy and safety of 2 oral doses of desmopressin compared to 20 micrograms. nasal spray and baseline values in the treatment of primary nocturnal enuresis.
MATERIALS AND METHODS: A multicenter study was done comparing oral dosages (200 and 400 micrograms.) of desmopressin (4-week, randomized, double-blind phase followed by 12 weeks of open label treatment with 400 micrograms.) to 20 micrograms. nasal spray in 66 adults and adolescents 12 to 45 years old with primary nocturnal enuresis.
RESULTS: No significant differences were found between the 2 doses of desmopressin tablets or between the tablets and 20 micrograms. nasal spray during the double-blind phase. However, patients who initially received 200 micrograms. desmopressin tablets experienced fewer wet nights after they completed 12 weeks of open label treatment when the dose was escalated to 400 micrograms. tablets. Those who received 400 micrograms. tablets initially maintained response during this phase. Desmopressin tablets were well tolerated at both dose levels: 96% of patients and 94% of physicians rated the tolerability as excellent.
CONCLUSIONS: Desmopressin tablets are an effective and safe alternative for treatment of nocturnal enuresis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996345

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Urinary incontinence in the elderly. Causes and treatment options.

Authors:  S Z Nasr; J G Ouslander
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 2.  Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors.

Authors:  Christian W Gruber; Markus Muttenthaler; Michael Freissmuth
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Direct palladium-mediated on-resin disulfide formation from Allocam protected peptides.

Authors:  Thilini D Kondasinghe; Hasina Y Saraha; Samantha B Odeesho; Jennifer L Stockdill
Journal:  Org Biomol Chem       Date:  2017-04-05       Impact factor: 3.876

4.  Alarm therapy and desmopressin in the treatment of patients with nocturnal enuresis.

Authors:  Basri Cakiroglu; Ersa Arda; Tuncay Tas; Aykut Bugra Senturk
Journal:  Afr J Paediatr Surg       Date:  2018 Jul-Dec

Review 5.  Comparative tolerability of drug therapies used to treat incontinence and enuresis.

Authors:  R G Owens; M M Karram
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

6.  On the Utility of Chemical Strategies to Improve Peptide Gut Stability.

Authors:  Thomas Kremsmayr; Aws Aljnabi; Juan B Blanco-Canosa; Hue N T Tran; Nayara Braga Emidio; Markus Muttenthaler
Journal:  J Med Chem       Date:  2022-04-14       Impact factor: 8.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.